Hubei Biocause Heilen Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Hubei Biocause Heilen Pharmaceutical has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1.3% per year. Hubei Biocause Heilen Pharmaceutical's return on equity is 4.6%, and it has net margins of 23.4%.
Key information
3.9%
Earnings growth rate
-5.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -1.3% |
| Return on equity | 4.6% |
| Net Margin | 23.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings
Nov 04
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Recent updates
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings
Nov 04Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%
Oct 30Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Revenue & Expenses Breakdown
How Hubei Biocause Heilen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 455 | 106 | 55 | 44 |
| 30 Jun 24 | 499 | 132 | 59 | 52 |
| 31 Mar 24 | 608 | 174 | 61 | 57 |
| 31 Dec 23 | 663 | 176 | 61 | 53 |
| 30 Sep 23 | 712 | 192 | 49 | 40 |
| 30 Jun 23 | 680 | 184 | 53 | 30 |
| 31 Mar 23 | 580 | 138 | 45 | 22 |
| 01 Jan 23 | 515 | 126 | 46 | 20 |
| 30 Sep 22 | 468 | 101 | 56 | 21 |
| 30 Jun 22 | 504 | 108 | 44 | 20 |
| 31 Mar 22 | 548 | 113 | 44 | 20 |
| 01 Jan 22 | 541 | 122 | 40 | 18 |
| 30 Sep 21 | 589 | 138 | 49 | 23 |
| 30 Jun 21 | 576 | 144 | 51 | 25 |
| 31 Mar 21 | 567 | 159 | 63 | 23 |
| 31 Dec 20 | 593 | 168 | 68 | 23 |
| 31 Dec 19 | 660 | 100 | 93 | 25 |
| 31 Dec 18 | 517 | 48 | 83 | 21 |
| 31 Dec 17 | 366 | 10 | 46 | 18 |
Quality Earnings: 301211 has a high level of non-cash earnings.
Growing Profit Margin: 301211's current net profit margins (23.4%) are lower than last year (26.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301211's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: 301211's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301211 had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 301211's Return on Equity (4.6%) is considered low.